Podcasts about dulaglutide

A class of medications known as GLP-1 receptor agonists has revolutionized the treatment of type 2 diabetes and obesity. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a hormone that stimulates insulin secretion and inhibits glucagon release, helping to regulate blood sugar levels and promote weight loss. In this podcast, we'll talk about the differences among some of the most well-known GLP-1 receptor agonists for type 2 diabetes. Ozempic (Semaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Primarily for type 2 diabetes (lower blood sugar and A1c); also approved for reducing the risk of major cardiovascular events like heart attack and stroke in adults with type 2 diabetes and known heart disease. Keep in mind, Wegovy (semaglutide) is a higher-dose version that's approved for weight loss. When you start taking Wegovy or Ozempic, you'll begin with a low dosage. Your prescriber will increase your dosage every four weeks until you reach the target amount. However, the specific dosage you inject will differ depending on the medication. The maximum dose for Ozempic is 2mg weekly, while the target dose for Wegovy is 2.4mg weekly. Rybelsus (Semaglutide) Form: Oral tablet Dosing Frequency: Once daily Uses: Lower blood sugar and A1c in people with type 2 diabetes. Rybelsus shares the same active ingredient as the injectable medications Ozempic and Wegovy. Ozempic is also approved for Type 2 diabetes, while Wegovy is approved specifically for weight loss. Rybelsus is available in three different strengths: 3 mg, 7 mg, and 14 mg. Similar to Ozempic, the dose is slowly increased every 4 weeks.  Good to know: It's important to take Rybelsus first thing in the morning with 4 oz of water. After taking it, you should wait at least 30 minutes before eating, drinking, or taking other medications. Failing to do so may reduce its effectiveness. Currently, Rybelsus is undergoing clinical trials to evaluate its effectiveness for weight loss. The trials involve higher doses than those approved for diabetes treatment. Results indicate that a 50 mg dose of oral semaglutide (Rybelsus) achieves weight loss comparable to Wegovy.  Trulicity (Dulaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes; and like Ozempic, it's also approved for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Like Ozempic and Rybelsus, you will start at a low dose to help reduce side effects. Your healthcare provider will then gradually increase the dose, balancing the management of side effects with the benefits of blood sugar control. The maximum dose for Trulicity is 4.5mg weekly. Victoza (Liraglutide) Form: Injectable Dosing Frequency: Once daily Uses: Type 2 diabetes; also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Victoza is one of three GLP-1 agonists approved for treating Type 2 diabetes in children aged 10 and older. The other options are Trulicity (dulaglutide) and Bydureon BCise (exenatide). More on this later. Ozempic, however, is only approved for use in adults. Saxenda and Victoza are both injectable medications containing liraglutide, but they are approved for different uses. Saxenda is FDA-approved for chronic weight management in people 12 and older, while Victoza is approved for treating Type 2 diabetes in people 10 and older. Victoza also helps lower the risk of major adverse cardiovascular events in adults with diabetes and heart disease. Both medications are injected once a day, starting with a low dose that is gradually increased over time. The target dose for Saxenda is 3 mg once daily, whereas the maximum dose for Victoza is 1.8 mg once daily. Byetta (Exenatide) Form: Injectable Dosing Frequency: Twice daily Uses: Type 2 diabetes. Additional Benefits: It has a shorter duration of action than other GLP-1 agonists, which may be preferable for some patients. Byetta, approved in 2005, was the first GLP-1 medication of its kind for diabetes. Its active ingredient, exenatide, is a synthetic version of a substance found in Gila monster saliva.  The recommended starting dose for Byetta is 5 mcg twice daily, administered within 60 minutes before your morning and evening meals. After one month, your healthcare provider may increase the dose to 10 mcg twice daily. Starting at a lower dose helps reduce stomach-related side effects. Bydureon BCise (Exenatide Extended-Release) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Extended-release formulation provides a more convenient dosing schedule compared to Byetta. Unlike Byetta, Bydureon BCise has a fixed dose of 2 mg administered once weekly, on the same day each week. It can be taken at any time of day, with or without food. Mounjaro (Tirzepatide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Dual action as it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, potentially offering enhanced efficacy in blood sugar control. Mounjaro is not approved for weight loss; however, its active ingredient, tirzepatide, is approved for weight loss under the brand name Zepbound. Typically, Mounjaro's starting dose is 2.5 mg once weekly for four weeks. By week 5, the dosage is often increased to 5 mg once weekly for another four weeks. Following week 9, if necessary for better blood sugar management, the dosage can be escalated to 7.5 mg weekly. It's important not to increase Mounjaro doses by more than 2.5 mg every four weeks. The maximum recommended dosage is 15 mg once weekly. Unlike Ozempic, Trulicity, or Victoza, Mounjaro is currently not approved for any heart-related uses. However, an ongoing clinical trial is assessing its effectiveness in reducing major adverse cardiovascular events in people with Type 2 diabetes. The study is anticipated to conclude in October 2024. Key Differences and Considerations The right GLP-1 agonist for you will likely come down to a few key factors like age, treatment goals, and underlying health conditions. Personal preferences like dosage frequency will also come into play. Dosing Frequency: Once weekly: Ozempic, Trulicity, Bydureon BCise, Mounjaro. Once daily: Rybelsus (oral), Victoza, Saxenda. Twice daily: Byetta. Administration Form: Injectable: All except Rybelsus (oral). Oral: Rybelsus. Indications: Type 2 Diabetes: All medications. Cardiovascular Benefits: Proven cardiovascular benefits: Ozempic, Trulicity, Victoza. Pediatric Use: Approved for children: Victoza (for children 10 years and older). Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market. 

Welcome to another engaging episode of 1D Talks! In today's "Nerd Chat Strength Edition," we delve into the fascinating world of strength training and sports nutrition. Our special guests are two renowned experts in the field: Greg Pyszczynski and Tom Sheppard.⏩ Episode Overview---------------------------✅ Understand the critical components of a successful strength training program.✅ Learn how to optimize nutrition for peak performance and recovery.✅ GLP-1s, Semaglutide, Wegovy, Exanatide, Dulaglutide, Trulicity. ✅ Discover practical tips and strategies to enhance your training regimen.✅ Real-life applications of strength training principles, with examples from football, MMA, powerlifting, and more.✅ Better understand coaches' philosophies and how they tailor their approaches to meet the needs of individual athletes.⏩ Stay Connected---------------------------❇️ Find Us on Social Media: @1stDetachment❇️ Expert-Formulated Supplements: 1stDetachment.com ❇️ Troponin Nutrition: TroponinNutrition.com❇️ EliteFTS: elitefts.com❇️ Tom Sheppard Instagram: @PhoenixPerformanceTrainingSupport the Show.** DISCLAIMER **The content on this channel is for entertainment and educational purposes only. 1st Detachment does not provide, endorse, or promote specific medical providers. We do not make warranties to its accuracy, application, and completeness. Our guests share their opinions and views on a variety of complex topics. Always seek advice from qualified medical practitioners. Do not disregard medical advice or delay seeking medical treatment due to the information presented on this channel.Consult with a physician before taking any over-the-counter medications, supplements, or herbs. This channel does not endorse medications, vitamins, or herbs, nor do we condone the use of illegal drugs.Consistent with community guidelines, we do not glorify the use of illegal drugs or the consumption of drugs illegally. A qualified medical professional should make decisions with each patient's health profile, current prescriptions, and medical history in mind.

Is there potential for recovery in patients who are withdrawn from life support? Find out about this and more in today's PeerDirect Medical News Podcast.

Join me with Dr. Damon McCune as we dive into the hot topic of Ozempic and its impact on the world of weight management. We explore not just Ozempic, but other groundbreaking weight loss drugs, discussing their potential, efficacy, and what bariatric patients specifically need to consider. Tune in to uncover the latest advancements in medical treatments for obesity and learn how these innovations can be part of a comprehensive approach to health and weight loss. Need Support ? www.theritelife.com support@theritelife.com

In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability Presenters:Jennifer Green, MDProfessor of MedicineDivision of Endocrinology and Duke Clinical Research InstituteDuke University School of MedicineDurham, North CarolinaCarol Hatch Wysham, MDClinical Professor of MedicineClinical EndocrinologistMultiCare/Rockwood ClinicSpokane, WashingtonLink to online program: https://bit.ly/48b6XnW

Today On Medical Grounds, we will be speaking with Dr. Heather Whitley. Dr. Whitley is a clinical professor in the Department of Pharmacy Practice at the Auburn University Harrison College of Pharmacy. She is a board certified pharmacotherapy specialist and a certified diabetes educator. Earlier this year, Dr. Whitley spoke with us about screening for diabetes in high-risk individuals. Today, she is back to talk about some new things going on in the diabetes and pharmacy world. This is part 1 of a two part series. In Part 1, Dr. Whitley will be discussing shortages in GLP-1 agonist drugs for diabetes and what pharmacists can do to address those shortages.Dr. Whitley recently published a paper in Clinical Diabetes about this topic:Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages(00:09) Introduction to Dr. Whitley(01:08) Publication on strategies for GLP-1 and GLP-1/GIP shortages(02:36) GLP-1 and GLP-1/GIP agonists, names, and dosing(04:15) Why are there shortages?(08:52) Alternatives(10:11) What happens if a patient misses a dose?(12:19) Re-initiation of medications(14:51) GLP-1 agonist equivalency(15:31) Substituting SGLT2s(17:16) Self-sourcing or online sourcing problems(21:51) Managing patient expectations and concernsVisit us at OnMedicalGrounds.com for more podcasts! You can subscribe through your podcast platform, our website, or follow us on social media for podcast updates and medical news. Some of our podcasts offer FREE CME/CE credits.LinkTreeTwitterLinkedInInstagram

The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis. Here are the GLP-1 RA drug makers and their drugs: Eli Lilly (ticker LLY) Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023. Dulaglutide sold as Trulicity. Novo Nordisk (ticker NVO) Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss. Liraglutide sold as Victoza for diabetes and Saxenda for weight loss. --- Support this podcast: https://anchor.fm/dumbmoney/support

The pronunciation of Trulicity® (dulaglutide) is the focus of this episode.  In my pronunciation episodes, I say a drug name, break it down into syllables, explain which syllable or syllable(s) have the emphasis, reveal the source(s) of the information, and put the written pronunciation in the show notes so that you see it and and use it right away. Having a colleague pick the drug name worked so well last month with Dr. Jennifer Marquez (May 2022) that I asked Allana Alexander, PharmD to pick the drug name for June 2022.  If you're interested in recommending the drug name for a future pronunciation episode on The Pharmacist's Voice Podcast, contact me through my website www.thepharmacistsvoice.com.  Just click on the “Contact” tab, and either fill out the form or leave me a voicemail message.  Thank you for listening to The Pharmacist's Voice ® Podcast Episode 155! Subscribe or follow for all future episodes!   Trulicity® = TRU - li - si - tee TRU is the syllable with the emphasis. Source:  Medication guide for Trulicity®   Dulaglutide = DOO la GLOO tide GLOO gets the primary emphasis.   DOO gets the secondary emphasis.   Source:  USP Dictionary Online (subscription-based resource) Mentioned in this episode Allana Alexander, PharmD on LinkedIn linkedin.com/in/doctorlany  A² Pharmacy Solutions (Greater Birmingham, Alabama area) http://a2pharmacysolutions.com  Instagram https://www.instagram.com/a2pharmacysolutions/  TikTok a2pharmacysolutions The Pharmacist's Voice Podcast Episode 148/Pronunciation Episode 4 (featuring Jennifer Marquez, PharmD) The Pharmacist's Voice Podcast Episode 142/Pronunciation Episode 3 The Pharmacist's Voice Podcast Episode 138/Pronunciation Episode 2 The Pharmacist's Voice Podcast Episode 134/Pronunciation Episode 1 Website for Trulicity® https://www.trulicity.com   Trulicity® Healthcare Provider Video https://www.trulicity.com/hcp  USP Dictionary Online sales page Merriam-Webster's online dictionary https://www.merriam-webster.com  Medication guide for Trulicity:  FDA's website or drug's website (2 different ways to get the same info)

Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. Get the upshot on best evidence from leading experts Drs Silvio Inzucchi and Rita Kalyani. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963267). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes https://www.fda.gov/media/71297/download Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1504720 Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1603827 Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042007 Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis of the EMPEROR-Reduced and DAPA-HF Trials https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/fulltext The SGLT2 Inhibitor Dapagliflozin in Heart Failure With Preserved Ejection Fraction: A Multicenter Randomized Trial https://www.nature.com/articles/s41591-021-01536-x A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL) https://clinicaltrials.gov/ct2/show/NCT04865770

Where are the biggest cardiovascular benefits for your patients with type 2 diabetes? Host Dr Silvio Inzucchi and cardiologist Dr Mikhail Kosiborod reveal winning strategies — for managing much more than just type 2 diabetes. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963270). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources New ACC Guidance on CVD Risk Reduction in Diabetes https://www.medscape.com/viewarticle/935218 Type 2 Diabetes in Adults: Management https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#blood-glucose-management Type 2 Diabetes and Causes of Sudden Cardiac Death: A Systematic Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525691/ Cardiometabolic Medicine – the US Perspective on a New Subspecialty https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410029/pdf/xce-9-070.pdf Antidiabetics, Glucagon-like Peptide-1 Agonists https://reference.medscape.com/drugs/antidiabetics-glucagon-like-peptide-1-agonists Antidiabetics, SGLT2 Inhibitors https://reference.medscape.com/drugs/antidiabetics-sglt2-inhibitors Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/31189511/ Mechanistic Insights Regarding the Role of SGLT2 Inhibitors and GLP1 Agonist Drugs on Cardiovascular Disease in Diabetes https://pubmed.ncbi.nlm.nih.gov/31381891/ SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-analysis of Cardiovascular Outcome Trials https://pubmed.ncbi.nlm.nih.gov/30424892/ Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial https://pubmed.ncbi.nlm.nih.gov/33736819/ Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1812389 CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis https://diabetesjournals.org/care/article/39/7/1108/37341/CV-Protection-in-the-EMPA-REG-OUTCOME-Trial-A Worldwide Inertia to the Use of Cardiorenal Protective Glucose-Lowering Drugs (SGLT2i and GLP-1 RA) in High-Risk Patients with Type 2 Diabetes https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01154-w Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/30291013/ High-Sensitivity C-Reactive Protein https://emedicine.medscape.com/article/2094831-overview#:~:text=hs%2DCRP%20is%20an%20important,predicts%20mortality%20and%20cardiac%20complications. Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists: 5 Things to Know https://www.medscape.com/viewarticle/960356 Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34215025/ Coronary Artery Calcification on CT Scanning https://emedicine.medscape.com/article/352189-overview

Dr Rinki Murphy discusses type 2 diabetes management with a focus on GLP- 1 receptor agonists.

Hertzel Gerstein talks with The Lancet Diabetes & Endocrinology about how dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes.

In today's episode we delve into the fascinating world of weight-loss medication, appetite suppressing drugs, and obesity treatment with obesity specialist and lipidologist Dr. Spencer Nadolsky 0:00 intro 1:39 - What factors drive obesity? 6:54 - Genetics factors behind obesity 11:25 - Weight loss medication - just how effective are they? 15:26 - GLP-1 analogs: Dulaglutide, Liraglutide, Semaglutide, etc 21:50 - Phentermine 28:51 - Sibutramine 30:51 -Naltrexone/bupropion 38:59 - Lorcaserin, Orlistat, other, less viable drugs 41:06 - Why are these drugs not widely available for everyone? 44:28 - Do people stay on these drugs permanently? 47:07 - Personal trainers and coaches being against these drugs 48:21 - Anything over the counter that's effective? 50:55 - Where can we find you? To apply to the new round of group coaching, you can book a time at: https://calendly.com/abel-csabai/ssd-transformation Or drop me an email to abel.csabai [at] gmail.com Angles 90 grips: https://angles90-the-first-dynamic-training-grip-worldwide.myshopify.com/?rfsn=5301938.a3640b Coupon code for 10% off ABELC10 insta: @ssdabel Find Dr. Nadolsky: insta: @drnadolsky https://renaissanceperiodization.com/team-member/spencer-nadolsky https://drspencer.com/

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. This issue will review: Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality Effects of iGlarLixi up to 52 weeks in type 2 diabetes Comparative effectiveness and safety of SGLT2 inhibitors vs. GLP-1 receptor agonists in Older Adults Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes   For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

Dr Tom Dover explains the new indication for dulaglutide (adjunct to standard of care to reduce the risk of MACE in T2D patients with established CVD OR multiple CVD risk factors) in the context of recent Australian and international guideline recommendations to consider CVD risk when selecting glucose lowering therapies. Practical implications for Australian GPs are discussed.

Dulaglutide is a GLP-1 agonist used in the management of diabetes. Dulaglutide has 4 different dosages that can be used to help lower A1C. As the dose goes up, so does the potential for adverse effects however. Like most of the GLP-1 agonists, dulaglutide is only available as an injection. Semaglutide is an exception to this. Nausea is the primary adverse effect of dulaglutide which some patients may get used to over time.

Lilly Diabetes invites you to listen to a podcast about Trulicity® (dulaglutide): Putting the Results Into Perspective: Trulicity’s Cardiovascular Outcomes Trial (REWIND) In this podcast episode, Dr. Eden Miller and Dr. Matthew Budoff discuss the relationship between type 2 diabetes and CV risk, the importance of addressing both hyperglycemia and CV risk in patients with type 2 diabetes, and treatment considerations for these patients. They will also discuss the design and results of the Trulicity CV outcomes trial, REWIND.  Please see full Prescribing Information, including Boxed Warning about possible thyroid tumors including thyroid cancer, Medication Guide and Instructions for Use.

Description: There are many challenges faced by residents, providers, and staff in LTC facilities, including the risk of hypoglycemia in residents with type 2 diabetes, the excessive reliance on sliding scale insulin, and comorbidities such as renal impairment. When managing LTC residents with type 2 diabetes, simplified treatment regimens with a low risk of hypoglycemia are preferred. Join us in this episode as Dr. Chad Worz and guest speakers Dr. Scott Drab and Dr. Naushira Pandya discuss how Trulicity, a GLP-1 RA, may be a suitable treatment option for adult LTC residents who need additional blood glucose control. SenioRx Radio https://www.ascp.com/page/SenioRxRadio Part of the Eli Lilly & Company - Pharmacy Podcast Network Series  See omnystudio.com/listener for privacy information.

Description: There are many challenges faced by residents, providers, and staff in LTC facilities, including the risk of hypoglycemia in residents with type 2 diabetes, the excessive reliance on sliding scale insulin, and comorbidities such as renal impairment. When managing LTC residents with type 2 diabetes, simplified treatment regimens with a low risk of hypoglycemia are preferred. Join us in this episode as Dr. Chad Worz and guest speakers Dr. Scott Drab and Dr. Naushira Pandya discuss how Trulicity, a GLP-1 RA, may be a suitable treatment option for adult LTC residents who need additional blood glucose control. SenioRx Radio https://www.ascp.com/page/SenioRxRadio Part of the Eli Lilly & Company - Pharmacy Podcast Network Series 

https://www.nejm.org/doi/full/10.1056/NEJMoa1806515 -- IVC filter after a severe injury = it is ok to wait 7 days https://www.nejm.org/doi/full/10.1056/NEJMoa1904143 antithrombotic therapy with afib after a pci and 1 year == just the DOAC https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31791-X/fulltext polypill for primary prevention just might work but likely need more research https://www.bmj.com/content/366/bmj.l4570 the more you exercise the more you live-- seems like a basic concept and it is easy to understand but sadly hard to follow for many https://www.ncbi.nlm.nih.gov/pubmed/31189511 dulaglutide can save non-fatal strokes and for just 20million dollars you can help the industry make a killing in this very flawed study

https://www.ncbi.nlm.nih.gov/pubmed/30347032  Terbinafine adverse effects are rare https://www.ncbi.nlm.nih.gov/pubmed/31189511 Dulaglutide prevents MACE but at a high price tag https://www.ncbi.nlm.nih.gov/pubmed/30853124   If you punch your buddy then get some buddy tape https://www.ncbi.nlm.nih.gov/pubmed/31076416 prediabetes gibes me a headache    https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Access-to-Hormonal-Contraception    Over the counter birthcontrol!! 

Dans cette 26e baladodiffusion, les Drs Luc Lanthier et Gabriel Huard discutent de l’efficacité CV du dulaglutide (Trulicity®) un antihyperglycémiant de la classe des agonistes des récepteurs du GLP-1, sur les événements cardiovasculaires chez les sujets avec diabète type 2, avec l’étude REWIND, en plus de réviser la littérature médicale de mai et juin 2019. … Continuer la lecture de « BC 026 – Efficacité cardiovasculaire du dulaglutide dans le diabète type 2 (étude REWIND) »

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti. Find more on Medicine Matters diabetes

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. This month we review articles on: 1. Cardiac Effects of Sullfonylurea-Related Hypoglycemia 2. Dulaglutide and Pancreas Safety 3. Gestational Diabetes and Cardiometabolic Risk in Offspring 4. Autologous Stem Cell-Derived Beta Cell Therapy for Diabetes 5. Cardiac Effects of Hypoglycemia in Type 1 Diabetes 6. Cost-effectiveness of Behavioral Cpunseling For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil S. Skolnik, M.D., Professor of Family and Community Medicine, Temple University School of Medicine; Associate Director, Family Medicine Residency Program, Abington Memorial Hospital. John J. Russell, M.D., Associate Professor of Family and Community Medicine, Temple University School of Medicine; Director, Family Medicine Residency Program, Abington Memorial Hospital.

In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.

Today in FirstWord:

Today in FirstWord: